Category Archives: Innovation

In India’s Fight Against Tuberculosis, Diagnostics Remains Poorly Understood

A lack of innovation in diagnostics is making Indians more prone to drug-resistant TB, which is difficult to treat and could be fatal. By Ankur Paliwal, The Wire | March 3, 2017 The end of an otherwise typical day in the winter of … Continue reading

Posted in Innovation, Patent, Uncategorized | Tagged | Leave a comment

Patent denied, price of prostate cancer drug may go down

The Indian Patent Office recently denied a patent for the drug Xtandi (Enzalutamide) by Japanese firm Astellas Pharma used in  treatment of prostate cancer. This decision comes in the light of the pre-grant opposition filed by pharma companies BDR Pharma, drug … Continue reading

Posted in Bayh Dole Act, March in rights, Patent, Patent Opposition, Sec 3 (d), Uncategorized | Tagged | Leave a comment

The U.S. Is Standing in the Way of Cheaper Drugs for the Poor

By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading

Posted in Innovation, R&D, TPP, Uncategorized, UNHLP report, WHO | Leave a comment

Just the Medicine

How the next president can lower drug prices with the stroke of a pen. By Alicia Mundy, Washington Monthly | Nov/Dec 2016 It’s hard to watch television or read a newspaper these days without seeing stories about outrageous prescription drug … Continue reading

Posted in Bayh Dole Act, Drug prices, Patent, R&D, Uncategorized | Leave a comment

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Indian drug regulator may scrap licence renewal; move may affect quality of medicines

By Prabha Raghavan, ET Bureau | October 8, 2016 NEW DELHI: India’s drug regulator proposes to scrap the renewal of licences and approvals for manufacturing and selling drugs and cosmetics in the country as part of efforts to remove hurdles … Continue reading

Posted in Clinical Trials, Uncategorized | Leave a comment

The Downfall Of Invention: A Broken Patent System

By Tahir Amin, The Huffington Post | August 17, 2016 The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to … Continue reading

Posted in Innovation, Patent, TRIPS, Uncategorized | Leave a comment